izpis_h1_title_alt

Vaccinomics and adversomics in the era of precision medicine : a review based on HBV, MMR, HPV, and COVID-19 vaccines
ID Omersel, Jasna (Author), ID Karas Kuželički, Nataša (Author)

.pdfPDF - Presentation file, Download (1,21 MB)
MD5: 2E038FCD3D785D335EE1283AB9340AAE
URLURL - Source URL, Visit https://www.mdpi.com/2077-0383/9/11/3561 This link opens in a new window

Abstract
Precision medicine approaches based on pharmacogenomics are now being successfully implemented to enable physicians to predict more efficient treatments and prevention strategies for a given disease based on the genetic background of the patient. This approach has already been proposed for vaccines, but research is lagging behind the needs of society, and precision medicine is far from being implemented here. While vaccinomics concerns the effectiveness of vaccines, adversomics concerns their side effects. This area has great potential to address public concerns about vaccine safety and to promote increased public confidence, higher vaccination rates, and fewer serious adverse events in genetically predisposed individuals. The aim here is to explore the contemporary scientific literature related to the vaccinomic and adversomic aspects of the three most-controversial vaccines: those against hepatitis B, against measles, mumps, and rubella, and against human Papilloma virus. We provide detailed information on the genes that encode human leukocyte antigen, cytokines and their receptors, and transcription factors and regulators associated with the efficacy and safety of the Hepatitis B and Measles, Mumps and Rubella virus vaccines. We also investigate the future prospects of vaccinomics and adversomics of a COVID-19 vaccine, which might represent the fastest development of a vaccine ever.

Language:English
Keywords:adversomics, COVID-19, genetics, hepatitis B, human Papilloma virus, MMR vaccine, precision medicine, vaccinomics
Work type:Article
Typology:1.02 - Review Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2020
Number of pages:22 str.
Numbering:Vol. 9, iss. 11, art. 3561
PID:20.500.12556/RUL-134726 This link opens in a new window
UDC:615.015:575.111
ISSN on article:2077-0383
DOI:10.3390/jcm9113561 This link opens in a new window
COBISS.SI-ID:35836931 This link opens in a new window
Publication date in RUL:27.01.2022
Views:524
Downloads:178
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Journal of clinical medicine
Shortened title:J. clin. med.
Publisher:MDPI
ISSN:2077-0383
COBISS.SI-ID:5405759 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:05.11.2020

Secondary language

Language:Slovenian
Keywords:genomika, farmakogenomika, cepiva, stranski učinki, humani papilomavirus, hepatitis B

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back